Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM
Status:
RECRUITING
Trial end date:
2027-01-31
Target enrollment:
Participant gender:
Summary
To explore the efficacy and safety of sintilimab, bevacizumab combined with pemetrexed and cisplatin in the treatment of malignant peritoneal mesothelioma, and to explore the biomarkers related to efficacy or safety.
Phase:
PHASE2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences